Robert Freedman talks with
ScienceWatch.com and answers a few questions about
this month's New Hot Paper in the field of
Psychiatry/Psychology.
Article Title: Initial phase 2 trial of a nicotinic
agonist in
schizophrenia
Authors: Freedman,
R;Olincy, A;Buchanan, RW;Harris, JG;Gold,
JM;Johnson, L;Allensworth, D;Guzman-Bonilla, A;Clement,
B;Ball, MP;Kutnick, J;Pender, V;Martin, LF;Stevens,
KE;Wagner, BD;Zerbe, GO;Soti, F;Kem, WR
Journal: AMER J PSYCHIAT
Volume: 165, Issue: 8, Page: 1040-1047, Year: AUG
2008
* Univ Colorado, Hlth Sci Ctr, Dept Psychiat C249 32,
Denver, CO 80262 USA.
* Denver VA Med Ctr, Dept Psychiat, Denver, CO USA.
(addresses have been truncated)
Why do you think your paper is highly
cited?
The targeting of nicotinic receptors for therapeutic treatment of mental
disorders is an emerging field of translational research. A long history of
basic inquiry into this mechanism of neurotransmission is now being used to
devise new treatment possibilities for patients.
Where do you see your research leading in the
future?
The future of psychiatric treatment involves translating basic research in
neurobiology into new therapeutic strategies. As Editor of the American
Journal of Psychiatry, where this paper was published, I believe that
journals should disseminate the results of early therapeutic investigations
to encourage other investigators to undertake similar translational
studies.
Robert Freedman, M.D.
Professor and Chair
Department of Psychiatry
University of Colorado
Denver, Colorado, USA Web
| Web |
Web
Why do you think your paper is highly
cited?
